Merck & Co. has speared an acquisition target, agreeing to pay $680 million for Harpoon Therapeutics and its pipeline of T-cell engagers. The deal will give Merck control of drug candidates that will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results